Maveron and Serena Ventures lead $7M Investment in safe, creativity-first AI for Kids

BROOKLYN, N.Y., Nov. 18, 2025 — Hapiko, a Brooklyn-based company building creative technology for children, announced today the launch of Stickerbox, the first AI-powered voice-to-sticker printer designed to bring kids’ imaginations to life.  The device requires no smartphone, no laptops, and offers hours of independent play – no adult help needed. Following a $7 million funding round led by Maveron (investors behind Lovevery) and Serena Ventures (founded by tennis champion Serena Williams), Stickerbox introduces a new category of creativity-first AI designed for safe, hands-on play.

“Stickerbox is one of the first products to make AI feel magical for kids and grounded for parents. It’s an exciting glimpse of what creative play will look like for the next generation,” said Jerry Lu, Partner at Maveron.

Unlike passive screen-based tools, Stickerbox encourages real-world, open-ended play. Kids can simply speak their ideas, from “a dinosaur on a skateboard” to “a Viking ship sailing through outer space” and watch as their imagination instantly becomes a high-quality black & white sticker. The kid-safe thermal printer produces unlimited creations that children can color, customize, and use to decorate their world.

“There’s nothing like a child’s imagination, how it sees the world and turns the everyday into magic,” said Arun Gupta, CEO of Hapiko. “We built Stickerbox as a springboard for that creativity: real stickers, no rules, just endless imagination manifested.”

Kid-Safe AI Meets Creative Freedom

Stickerbox was built from the ground up for children’s safety and privacy. It operates with minimal data collection, no cameras, it only listens when given permission, and has built-in moderation filters that ensure every image is age-appropriate.

“As both an investor and a mother, I’m passionate about tools that empower children to create and express themselves safely,” said Serena Williams, Founder of Serena Ventures. “Stickerbox shows how technology can enhance childhood creativity – not replace it.”

“We designed our AI system with intention,” added Robert Whitney, CTO of Hapiko. “Every decision, from privacy to prompt safety, was made to give families peace of mind while inspiring kids to think bigger.”

Key Features & Benefits

Designed with both fun and functionality in mind, Stickerbox features:

• Voice-to-Image Generation: Kids simply describe what they imagine and Stickerbox instantly creates a printable sticker.
• Hands-On Creativity: Built to minimize passive screen time, Stickerbox encourages real-world, tactile play.
• Thermal Printing: Ink-free technology delivers crisp outlines, no mess or maintenance required. The paper is BPA and BPS-free so parents can feel confident this product is safe for use.
• Kids-centric AI: Purpose-built for young creators, Stickerbox uses Kid-safe AI within a durable, family-friendly design that prioritizes privacy, safety, and ease of use.

“We’re starting with stickers because they’re the perfect bridge between imagination and the real world,” said Robert Whitney. “But this is just the beginning,  Kids have so much creative potential, and we’re really excited to see where things go when they’re given safe tools made just for them.”

Stickerbox is now available in the US market at stickerbox.com for $99.99.

About Hapiko

Hapiko is a Brooklyn-based company building creative technology for the next generation. By combining child-centric design with the possibilities of kid-safe AI, Hapiko is redefining how kids play and express their imagination. The company is proudly backed by Maveron and Serena Ventures.

Media Contact:
5W Public Relations
[email protected]

SOURCE Hapiko

LOS ANGELES, Nov. 18, 2025 — Big Rentals, the Los Angeles-based equipment rental platform modernizing the $80+ billion U.S. equipment rental industry, today announced it has raised $2.8 million in seed funding. The round was led by SNAK Venture Partners with participation from Ironspring Ventures, Forum Ventures, Jason Calacanis’ LAUNCH Fund, and NuFund Venture Group.

The funding will accelerate Big Rentals‘ expansion into the construction and heavy equipment segment, building on strong early traction in the category through its nationwide partner network. It will also support continued development of HQRent.com, the company’s AI-powered software that helps independent rental businesses run online by managing bookings, payments, and fleet operations in one place.

“For too long, local rental companies and small business owners have had to stitch together outdated tools, paper, and spreadsheets,” said Pablo Fernandez, Co-Founder and CEO of Big Rentals. “We put the same technology used by national chains into the hands of independent operators, making it easy and affordable for anyone to start and scale a professional rental business.”

Founded in 2023, Big Rentals is a dual-sided platform that combines a national rental marketplace with modern operating software for independent equipment owners. Rental businesses use Big Rentals to automate scheduling, payments, and inventory, replacing legacy workflows with streamlined, digital operations. The marketplace brings new demand directly to local operators, driving higher utilization and unlocking new revenue opportunities across the U.S.

The investment marks growing recognition of Big Rentals‘ pioneering mission to modernize a historically offline industry. “Big Rentals is transforming an overlooked yet essential backbone of our economy. Pablo and the team are building a category-defining marketplace, and we’re thrilled to back a founder who combines deep industry insight with a software-first mindset,” said Sonia Nagar, Co-Founder of SNAK Venture Partners, who will join the Big Rentals board. Nagar brings extensive experience scaling leading marketplaces including BacklotCars and Sittercity, with investments in Machinery Partner, Cameo, and Coinbase at Pritzker Group Venture Capital.

Surging demand for equipment rentals is driven by record U.S. manufacturing investment, massive infrastructure projects, and a nationwide data center boom. U.S. manufacturing construction is at $223 billion – well above historic highs – and data center construction hit a $40 billion annual run rate this year, up 30%. As contractors shift from owning to renting, the $80+ billion equipment rental market is being reshaped in real time. In this new wave of American reindustrialization, Big Rentals‘ is positioned to unify the fragmented long tail of suppliers and capture the next decade of growth with a technology-first platform built for small businesses.

About Big Rentals

Big Rentals builds technology for the U.S. equipment rental industry, helping independent rental businesses manage bookings, payments, and inventory online. The platform uses AI automation to simplify scheduling and operations for small business owners. Founded in 2023 and headquartered in Los Angeles, CA and Nashville, TN, Big Rentals is backed by SNAK Venture Partners, Ironspring Ventures, LAUNCH Fund, Forum Ventures, and NuFund Venture Group.

SNAK Venture Partners, Ironspring Ventures, LAUNCH Fund, Forum Ventures, and NuFund Venture Group

Learn more at bigrentals.com.

Media Contact:
Name: Ludington Media on behalf of Big Rentals
Email: [email protected]
Phone: 551-795-5950

SOURCE Big Rentals

Nudge Security is the only solution that secures AI and SaaS at the Workforce Edge—the critical point where employees make technology decisions that shape the organization’s security posture. Rather than relying solely on reactive monitoring or restrictive controls that slow business innovation, Nudge Security delivers automated, policy-driven guardrails that reach employees in real-time, transforming security from a barrier to productivity into a natural part of how work gets done.

“Nudge Security is at an exciting time in their journey and we’re thrilled to partner with Russ, Jaime, and the team,” said Morgan Mahlock, Director at Cerberus Ventures. “Nudge has cultivated incredible customer loyalty due to its intuitive product that both security teams and employees appreciate for its ease of use. It can deliver immediate value by providing an automated inventory of the SaaS and AI tools being used across an organization. With the vision to expand governance of interactions with SaaS and AI at the Workforce Edge, Nudge will become even more essential for highly distributed, AI-first organizations.”

Since its initial launch in October of 2022, Nudge Security has experienced exponential growth, achieving 3x growth in ARR for two consecutive years, onboarding nearly 200 customers, and delivering rapid product innovation to address customers’ needs for scalable security and governance of workforce use of AI and SaaS.

The explosion of AI , particularly AI embedded throughout the SaaS ecosystem, has introduced unprecedented security challenges as organizations now grapple with hundreds of AI-enabled applications, complex networks of integrations, and non-human identities with access to sensitive data across their environment.

“The difference between AI apps and SaaS has all but disappeared—almost every app has embedded AI capabilities, agents, and integrations. In order to secure workforce AI use at scale, you need to consider the entire SaaS ecosystem, including all SaaS and AI tools, their integrations, and the non-human identities that connect them,” said Russell Spitler, Co-Founder & CEO of Nudge Security. “This funding will enable us to continue to expand our capabilities and help organizations confidently embrace innovation while maintaining security and control.”

Customer growth

Customers  include forward-thinking IT and security teams at cloud-native organizations spanning software, financial services, healthcare, biotechnology, entertainment, and more.

“Nudge Security has been a big win for our security program at Reddit,” says Fredrick Lee, CISO of Reddit. “Within hours of deployment, we gained complete visibility into our SaaS footprint across the organization. It’s rare to find a solution that’s both incredibly powerful and remarkably easy to use.”

Product Innovation

In the last 12 months, Nudge Security has shipped over 60 feature releases, adding significant new capabilities to improve AI governance, harden security posture, combat identity security risks, and mitigate third-party risks.

“Our team’s ability to innovate at this pace is a direct reflection of our deep understanding of the challenges our customers face,” said Jaime Blasco, Co-Founder & CTO of Nudge Security. “We’re not just building features—we’re solving real problems that security and IT teams encounter every day as they navigate the complexities of AI adoption and SaaS sprawl. This funding allows us to continue pushing the boundaries of what’s possible and deliver unparalleled value to organizations looking to embrace innovation without compromising on security.”

Notable Nudge Security capabilities:

• Day One discovery of the entire SaaS and AI footprint including apps, integrations, human and non-human identities, user activities, and more
• Scalable AI security and governance with visibility into AI apps, users, and integrations as well as AI embedded in other SaaS apps via AI agents and MCP servers
• Proprietary risk intelligence to accelerate vendor security assessments, alert on SaaS supply chain breaches, and surface other high-priority risks
• Automated guardrails that nudge the workforce toward safe SaaS and AI adoption, delivered just in time in the browser as well as via Slack and Teams
• Security posture monitoring to continually assess app configurations, integrations, and identity security against best practices, complete with step-by-step remediation guidance and orchestration workflows
• Identity security and governance workflows to identify and fix poor identity hygiene, streamline user access reviews, and automate employee offboarding

Comprehensive SaaS and AI Security Governance from Day One

Nudge Security offers a fully-functional free 14-day trial which delivers a complete inventory of all SaaS and AI apps, users, and integrations after a quick 5-minute set-up. The trial is completely self-driven with no credit card or sales conversation required to get started.

About Nudge Security

Nudge Security  delivers SaaS and AI security governance at the Workforce Edge—where employees make thousands of technology decisions daily. Our automated, policy-driven guardrails reach employees when and where they work, enabling rapid technology adoption while minimizing risk and sprawl. Through unrivaled discovery capabilities, AI-driven risk insights, and behavioral science-based engagement, we make security a natural part of how modern work gets done rather than an obstacle to innovation. Nudge Security was founded in 2021 by Russell Spitler and Jaime Blasco and is backed by Cerberus Ventures, Ballistic Ventures, Forgepoint Capital, and Squadra Ventures.

Learn more at www.nudgesecurity.com and follow Nudge Security on LinkedIn, Reddit, X, BlueSky, and Instagram.

SOURCE Nudge Security

Firm Surpasses $1.75 Billion in Regulatory AUM Strengthening Its Position as a Leading Private Equity Firm Focused on Consumer Brands and the Supply Chain and Services Businesses that Empower Them

LOS ANGELES, Nov. 18, 2025 — Monogram Capital Partners (“Monogram”), the Los Angeles-based private equity firm focused on building the next generation of enduring consumer businesses, has closed its third fund, Monogram Capital Partners Fund III, at its $350 million hard cap. The fund was substantially oversubscribed, reflecting strong demand from both returning and new investors and bringing Monogram’s total regulatory assets under management (RAUM) to approximately $1.75 billion.

Fund III drew continued commitments from long-standing Limited Partners who have partnered with Monogram since inception, as well as new institutional investors. The investor base consists of prominent endowments, foundations, family offices, funds of funds, and other institutions. This successful close underscores investors’ confidence in Monogram’s differentiated approach and marks another major milestone in Monogram’s evolution as a leading partner to category-defining consumer businesses.

A Differentiated Approach to Consumer Private Equity

Founded in 2014, Monogram typically partners with founders and family-owned consumer businesses as their first institutional investor, helping professionalize, scale, and sustain growth while preserving their entrepreneurial cultures. Unlike many of its peers that invest exclusively in consumer brands, Monogram’s model bridges both sides of the ecosystem, partnering with category-defining consumer companies and the supply chain and services businesses that power them. This complimentary dual mandate creates a distinctive flywheel of insight and operational synergy, aimed to fuel outsized growth and defensible value creation. 

“Our mission has always been to build enduring consumer businesses by pairing deep operational expertise with a long-term partnership mindset,” said Jared Stein, Co-Founder and Partner at Monogram Capital. “We view ourselves as the bridge between family-held businesses and large-cap institutional capital–helping scale companies that deliver exceptional value to consumers, employees, and communities alike.”

“Closing Fund III represents a significant milestone for our team and our investors,” said Stein. “We are deeply grateful for the trust placed in us and excited to continue building the next generation of enduring consumer businesses.”

Delivering Repeatable Outperformance

Monogram’s strong performance has been driven by a disciplined, data-informed investment process and a hands-on operational partnership model. The firm’s portfolio has achieved ~3x revenue growth and >600bps EBITDA margin expansion in aggregate across all investments made at least 5 years ago. The firm’s portfolio reflects deep industry expertise – spanning category disruptors and essential service providers alike.

Representative investments in the firm’s sectors of focus include:

• OLIPOP – a leading functional-soda pioneer recently valued at $1.85 billion
• Archer – a better-for-you meat-snack platform scaled 50x to ~$350 million of gross revenue
• Grand Fitness — a leading national Planet Fitness franchisee
• Kidfresh—a category leader in better-for-you frozen food distributed nationwide
• Precision Tri-State – one of the largest garage-door repair franchisee platforms in the nation
• D.S. & Durga — a premium fragrance business
• Vasco – a rapidly expanding sports-surfacing services provider to K-12 schools
• Chewy.com – a leading specialty pet retailer sold to PetSmart for $3.3 billion

Monogram’s recent exit of Western Smokehouse – a 40-year family held business that Monogram scaled from one to seven facilities, culminating in >1,200 jobs all while scaling EBITDA >10x- reinforced the firm’s track record of extending the legacy of family-held businesses and building durable value.

Positioning for the Next Chapter

With Fund III, Monogram will continue to execute its differentiated investment strategy across four core verticals: Food & Beverage, Beauty & Personal Care, Pet, and Consumer/Business Services. The firm also plans to expand its investment team and operating partner program to further institutionalize its platform and accelerate the impact of its portfolio.

“With the closing of this fund, we will add greater depth to our team and resources across the firm,” said Oliver Nordlinger, Co-Founder and Partner.  “These efforts to further institutionalize Monogram are in service of building an enduring firm for many funds to come.”

Monogram has repeatedly demonstrated a distinctive playbook for acquiring and scaling highly differentiated consumer businesses by deploying targeted operational resources and deep category insight to accelerate growth and compound market leadership. With this fund, Monogram will continue to identify and support the next generation of consumer champions.

Lazard acted as placement agent for Fund III and Latham Watkins LLP served as legal adviser.

About Monogram Partners

Headquartered in Los Angeles, CA, Monogram Capital Partners currently manages approximately $1.75B in RAUM, focusing exclusively on investing in leading consumer businesses, supply chain partners, and service providers. With a collaborative and operationally driven investment approach, Monogram typically serves as the first institutional partner to entrepreneurs and family owners—helping them build sustainable, category-leading businesses. For more information on Monogram Capital Partners, please visit:

http://www.monogramcapital.com

SOURCE Monogram Capital Partners

• Awarded grant from The Michael J. Fox Foundation will support the advancement of Vincere’s USP30 inhibitors and accompanying biomarkers for Parkinson’s disease through IND-enabling studies that will pave the way towards Phase 1 clinical trials
• Vincere’s USP30 inhibitors have the potential to be first-in-class and provide disease-modifying benefit to millions of patients with Parkinson’s disease
• This award builds on prior MJFF support of Vincere’s preclinical research in 2019 and 2022

CAMBRIDGE, Mass., Nov. 18, 2025 — Vincere Biosciences today announced the receipt of a $5 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through its Therapeutics Pipeline Program, which supports the advancement of promising therapies through preclinical and clinical stages. The initiative focuses on candidates with strong potential to slow or halt disease progression or alleviate burdensome symptoms for those living with Parkinson’s disease.  The funding accelerates Vincere’s lead USP30 inhibitor, a potentially first-in-class therapeutic designed to modify the course of Parkinson’s disease, through IND-enabling studies toward a 2026 clinical trial initiation. In parallel, the grant will also fund Vincere’s biomarker development efforts to evaluate target engagement and guide clinical translation, strengthening the foundation for future human studies.

“The Michael J. Fox Foundation remains steadfast in our mission to accelerate the development of transformative treatments and, ultimately, a cure for Parkinson’s disease,” said Jessica Tome Garcia, PhD, MJFF’s lead scientific program manager. “Our collaboration with Vincere Biosciences over the years has supported the advancement of research targeting mitochondrial dysfunction, a key driver of Parkinson’s pathology. This next phase of work builds on that foundation and represents important progress toward disease-modifying therapies that could meaningfully improve patients’ lives.”

Targeting the Root Cause of Neuronal Vulnerability

Mitochondrial dysfunction and impaired mitophagy are central features of PD pathophysiology. Mitophagy, the selective recycling of damaged mitochondria, is essential for maintaining neuronal health. In PD, this process is often compromised, leading to toxic buildup of defective mitochondria that accelerates neurodegeneration.

Vincere aims to restore mitochondrial quality control and prevent the progression of neuronal injury by selectively inhibiting USP30, a mitochondrial deubiquitinating enzyme that acts as a negative regulator of mitophagy. By targeting the cellular processes at the root of Parkinson’s, Vincere’s approach has the potential to not only slow disease progression but also improve quality of life for millions living with PD.

“Mitochondria sit at the crossroads of Parkinson’s and aging (the biggest risk factor for Parkinson’s),” says Dr. Spring Behrouz, co-founder and CEO of Vincere, “fix the mitochondria and you strike at the root of the disease. MJFF’s support helps us move that science from the lab to the clinic.”

Transitioning from Discovery to Clinic

MJFF’s award will fund critical IND-enabling studies, including pharmacology, toxicology, and regulatory workstreams. These studies will establish the foundation required for a successful Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA), marking the transition of Vincere’s program from preclinical development to the clinic. This award builds on prior MJFF support, which continues to move Vincere’s USP30 inhibitor program forward.

“It’s been exciting to see growing enthusiasm for USP30 since our AI platform prioritized this target in 2018. The new support from MJFF positions the company well for ongoing partnering discussions with larger organizations who may accelerate clinical development of this promising approach,” says Andy Lee, co-founder and CBO of Vincere.

About Vincere Biosciences Inc.
Vincere Biosciences is a Boston-based biotechnology company developing small-molecule therapeutics that improve mitochondrial repair and recycling to address neurodegeneration and age-related conditions. The company’s lead program targets USP30, an enzyme that impairs mitophagy, with an oral, brain-penetrant development candidate now moving through IND-enabling studies for Parkinson’s disease. Vincere integrates AI-guided discovery with mechanistic validation to advance medicines aimed at underlying cellular causes of disease. Learn more at www.vincerebio.com

Contact: Anahit Campbell,
Strategic Initiatives Manager,
Vincere Biosciences
Phone: 857-245-9492
Email: [email protected]

SOURCE Vincere Biosciences

BOSTON, Nov. 17, 2025 — Nanoramic, Inc. (“Nanoramic”), a pioneer in advanced batteries, today announced it has secured a total of $54 million for its Series 1 equity financing. The round includes a recent investment from new partner PEP Capital, as well as repeat investments following existing participation in this round from Samsung Ventures and Top Material.

This financing round also includes prior investments from co-leads General Motors Ventures and Catalus Capital, alongside ITOCHU Corporation, Fortistar Capital, and WindSail Capital Group. The participation from a world-class syndicate of new and existing investors underscores significant market confidence in Nanoramic’s technology and its clear path to commercial adoption across a broad range of battery applications.

Nanoramic is working with key strategic partners including Samsung SDI, General Motors, and other industry leaders to accelerate the global deployment of Nanoramic’s Neocarbonix® products under an asset-light business model. This follows a successful 2025, which saw the company complete key qualification programs with public and private sector partners across multiple applications and chemistries. Today, Nanoramic’s standardized Neocarbonix® products are qualified and available via manufacturing partners across the globe. The company is positioned to support GWh-scale demand, with commercial shipments scaling up and shifting to global manufacturing sites in 2026.

Nanoramic’s proprietary Neocarbonix® technology and products are a force multiplier for the battery industry, designed to drop into existing manufacturing lines for rapid adoption. It is a PFAS “forever chemical”-free solution that eliminates the need for conventional NMP solvents, enhancing manufacturing sustainability and worker safety. The technology delivers far-reaching improvements in battery cost, energy density, power, and fast-charging performance.

“Samsung Ventures is excited to continue our support for Nanoramic given the significant progress made over the past year. We continue to believe in their technology and its potential to impact multiple energy storage applications through lower cost, higher performance, or reduced environmental impact,” said a representative from Samsung Ventures.

Brent Saiontz, Partner at PEP Capital, said, “As global energy demand continues to surge, advanced battery innovation is essential. We’re proud to support Nanoramic as they commercialize a battery platform that delivers superior performance at lower cost. With broad applicability across industries and seamless integration into existing technologies and manufacturing lines, Nanoramic provides a practical, scalable path to better batteries today.”

“As co-leads of this financing, we are impressed by Nanoramic’s execution and success in transitioning from validation towards global commercialization. Their asset-light, drop-in solution provides a clear path to market adoption, addressing the energy storage industry’s critical needs. We are proud to support their scale-up as they become a key leader in the energy transition,” said Saif Qazi, Vice President at Catalus Capital.

John Cooley, Nanoramic CEO and Founder, said, “With the final closing of this round, Nanoramic has secured a portfolio of best-in-class customers and partners. These partnerships will help bring mass production of our Neocarbonix product to all major lithium-ion applications by 2027. Our asset-light model will benefit from the trading expertise of ITOCHU, the manufacturing expertise of Top Material, and the commercial prowess and broad application exposure of our most major customers including General Motors, Samsung SDI, and others. At Nanoramic, we will continue to successfully execute our plans toward global adoption now accelerated with the support of our new partners.”

About Nanoramic, Inc.
Nanoramic, Inc. is an industry-leading energy storage and advanced materials company that has developed an innovative battery technology, Neocarbonix®. Nanoramic is commercializing Neocarbonix to transform energy storage for all battery applications: increasing energy density and longevity, while reducing costs and improving sustainability. Nanoramic works with some of the world’s largest automakers, consumer electronics companies, and battery manufacturers to develop and commercialize batteries made with Neocarbonix. To learn more, visit www.nanoramic.com.

SOURCE Nanoramic, Inc.

First Closing of Breakthrough Properties Growth Portfolio II  Builds Upon Successes of Inaugural Fund

LOS ANGELES, Nov. 17, 2025 — Breakthrough Properties, a joint venture of Tishman Speyer and Bellco Capital, today announced the first closing for its Breakthrough Properties Growth Portfolio II fund, which will invest in a diversified portfolio of Class A life science real estate across leading innovation clusters in the United States and Europe.

Breakthrough’s $430 million first closing amount reflects both direct capital and co-investment commitments and builds upon the achievements of Breakthrough’s $3 billion inaugural life science investment fund, which closed in 2022.

The only dedicated life science real estate manager active across the U.S., U.K. and continental Europe, Breakthrough used its first fund to invest in a market-leading portfolio of projects spanning nearly six million square feet. Its current life science assets encompass purpose-built developments, value-add conversions and core/core+ properties across eight preeminent biopharma markets. 

Breakthrough’s signature projects, such as Torrey Heights in San Diego, One Helix in Amsterdam and One Milestone at the forthcoming Harvard Enterprise Research Campus in Boston, have already attracted many of the world’s leading life science firms. More than 60 percent of its global portfolio is currently leased to leading investment-grade companies, including Pfizer, AstraZeneca, Eli Lilly, Bristol Myers Squibb, BD and Roche. 

Participants in the first closing included institutional and private investors such as global asset managers, investment advisors, pension funds and family offices. Breakthrough, which plans to hold subsequent closings for the fund in 2026, will invest across a range of life science asset profiles and markets, targeting a blended value-add return.

“This closing aligns with the most compelling investment window we’ve seen in years,” said Dan Belldegrun, Chief Executive Officer for Breakthrough Properties. “Transitory market dynamics have generated the opportunity to acquire high quality assets at heavily disrupted pricing and to capitalize on the sector’s long-term structural tailwinds. The incredible power of science is only accelerating, generalist investors are retreating and new supply is entirely shut off. We believe these are precisely the ingredients for a fantastic investment vintage. We’re grateful to our partners for supporting Breakthrough’s exciting next chapter.”

Tishman Speyer CEO and Breakthrough Co-Chairman Rob Speyer said, “The first close of Breakthrough’s second fund demonstrates the trust we’ve built with our investment partners. Our initial fund delivered proof of concept. This fund allows us to flex all of Breakthrough’s muscles and scale an exceptional portfolio.”

Breakthrough Properties Chief Investment Officer Dan D’Orazi added, “Our investment approach will continue to center around Class A assets in prime locations, with an emphasis on attractive entry points and improving market fundamentals. Breakthrough’s dedicated life science platform, supported by our partners at Tishman Speyer and Bellco Capital, forms a deep expertise, relationship network and global reach that uniquely positions us to capitalize on opportunities emerging across the market.”

Driven by Bellco Capital and Tishman Speyer’s demonstrated success and established networks, 70 percent of Breakthrough’s leasing has been secured through direct relationships with premier life science users. 

Breakthrough is led by an experienced management team with a proven track record of acquiring, developing and operating life science real estate. The firm seeks to employ a user-driven approach and to provide unique insights on where science is trending to deliver a higher standard of quality with a focus on superior design, flexible buildouts and best-in-class amenities. 

Breakthrough targets LEED Gold certification at all its U.S. developments and BREEAM Outstanding across its U.K. and European Union projects. In 2025, the Global Real Estate Sustainability Benchmark (GRESB) ranked Breakthrough first amongst its Americas group peers in the Technology/Science sector, highlighting the team’s commitment to delivering high quality, sustainable research campuses for its clients. 

In addition to creating and cultivating full-service ecosystems, Breakthrough provides access to life science industry pioneers and mentorship services from its world-renowned Scientific Advisory Board and an extensive venture capital network.

About Breakthrough Properties ( btprop.com )
Formed in 2019 as a joint venture between global real estate owner, developer, and investor Tishman Speyer and biotechnology investment firm Bellco Capital, Breakthrough Properties is a life science real estate development company that leverages cross-sector collaboration to deliver environments that foster innovation and scientific breakthroughs. Breakthrough Properties’ mission is to acquire, develop and operate the best life science properties in leading urban technology centers around the world and support scientific innovation across biotechnology, agriculture, and nutrition. Breakthrough combines Tishman Speyer’s decades of global real estate development experience with Bellco Capital’s industry-making biotechnology entrepreneurship to reimagine environments where companies can create life-changing therapies for patients.

Forward Looking Statements
This press release may contain forward-looking statements within the meaning of the federal securities laws. Any such forward-looking statements are subject to risks and uncertainties, and actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. Furthermore, Breakthrough Properties disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes. Target returns are neither a guarantee nor a prediction of future performance and are based on various assumptions. No guarantee is made that such assumptions will materialize as expected or that investments will achieve such targeted results. The term “client” as used herein describes a life sciences firm that is a tenant of Breakthrough or other tenant of a property.

Non-U.S. Persons
This press release is not intended to be distributed, directly or indirectly, outside of the U.S. and is not directed at investors located in non-U.S. jurisdictions.

Photo – https://mma.prnewswire.com/media/2824717/Breakthrough_Properties__Torrey_Heights_by_Breakthrough.jpg

BOSTON, Nov. 17, 2025 — Bambusa Therapeutics, Inc. (“Bambusa”), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I&I), today announced the completion of its oversubscribed Series A-2 financing, closed at a substantial valuation step-up over the prior round.

This Series A-2 financing reflects strong participation from Bambusa’s existing investors, including Athos KG, RA Capital Management, INCE Capital, Redmile Group, BVF Partners L.P., Salvia GmbH, Janus Henderson Investors, Invus, ADAR1 Capital Management, and Dawn Biopharma (an investment platform controlled by KKR). Their continued commitment highlights growing confidence in Bambusa’s highly differentiated bispecific platform, rapid execution, and clinical momentum.

Proceeds will accelerate the development of BBT003 and BBT004, extending the company’s proven capability to move programs swiftly from concept to the clinic.

“In just 18 months, our team has advanced two bispecific programs, BBT001 and BBT002, from development candidate to clinical proof-of-concept, an unprecedented pace in I&I biologics, demonstrating what a small, highly coordinated team can achieve in a short period of time,” said Dr. Shanshan Xu, Founder and Chief Executive Officer of Bambusa Therapeutics. “This new financing enables us to apply that same momentum to BBT003 and BBT004. Closing the round at a significantly increased valuation is a clear reflection of the strength of our data, the speed and quality of our execution, and the deep conviction from our investors. 2026 will be a catalyst-rich year for Bambusa with more than 10 clinical readouts across multiple I&I indications.”

BBT001 and BBT002 — both built on Bambusa’s half-life-extended bispecific architecture — have progressed into Phase I studies in dermatology and respiratory indications, realizing the founding ambition to create transformative medicines that reshape the I&I landscape. BBT003 and BBT004 will be developed in gastroenterology and rheumatology, leveraging the same development engine that has driven Bambusa’s early clinical velocity.

Dr. Derek DiRocco, Partner at RA Capital Management, commented: “RA Capital Management is delighted to continue to support Bambusa as they progress their portfolio of potentially best-in-disease bispecific antibodies for various I&I indications deeper into the clinic. In the nine months since we led the Series A-1 financing, we have been thrilled with the rapid and flawless execution delivered by the Bambusa team. Over the next year we eagerly look forward to the extensive clinical data sets that will highlight the immense value across the Bambusa portfolio.”   

Key uses of proceeds:

• Advance BBT003 and BBT004 through IND-enabling studies and into early clinical development, maintaining Bambusa’s pace of advancement.
• Broaden Bambusa’s bispecific antibody platform into new I&I indications and deepen the pipeline.
• Strengthen core development infrastructure to support rapid progression through upcoming clinical and regulatory milestones.

About Bambusa Therapeutics

Bambusa Therapeutics is a clinical-stage biotechnology company developing a portfolio designed to transform care across a wide spectrum of chronic diseases. Powered by an innovative antibody engineering platform featuring half-life extension and high-concentration subcutaneous delivery, Bambusa’s vision is to deliver transformative medicines for patients across every stage of life — setting a new pace for the next era of I&I therapeutics. For more information, visit www.bambusatx.com.

• BBT001 is a first-in-class half-life-extended bispecific antibody targeting IL-4Rα and IL-31 with best-in-disease potential. It is currently in Phase I development for atopic dermatitis and other Type 2 inflammatory skin diseases.
• BBT002 is a first-in-class half-life-extended bispecific antibody targeting IL-4Rα and IL-5 with best-in-disease potential. It is currently in Phase I development for Type 2 inflammatory disorders including COPD, asthma, CRSwNP, eosinophilic esophagitis, and food allergy.
• BBT003 and BBT004 are preclinical programs focused on gastroenterology and rheumatology, respectively.

SOURCE Bambusa Therapeutics, Inc.

New Funding to Accelerate Platform Growth, Support New Feature Development, and Expand Geographic Reach

MENLO PARK, Calif., Nov. 17, 2025 — Shipday, a global delivery and logistics technology platform serving small and medium-sized businesses (“SMBs”), today announced it has raised $7 million in Series A funding co-led by ECP Growth (“ECP”), a leading growth stage investment firm focused on products, solutions, and technologies across the consumer value chain, and Ibex Investors Mobility VC (“Ibex”), an early-stage venture capital fund focused on mobility, logistics, and manufacturing, with additional participation from B Capital and Supply Chain Ventures. The company previously raised a seed round from B Capital in 2023, bringing its total funding to over $10 million.

Designed for restaurants and other local retailers, Shipday’s platform enables merchants to manage direct delivery orders efficiently while maximizing profitability and improving customer loyalty. With this new funding, Shipday will deepen its investments in new platform features and integrations, agentic AI automations, and an expanded geographic reach, furthering the company’s goal to offer instant access to modern delivery automation solutions to businesses of all sizes across the globe. Among these innovations is AgentFlow, Shipday’s new AI-powered automation engine that functions as a self-driving operating system for local deliveries. By leveraging intelligent agents to streamline dispatch, customer support, and marketing, AgentFlow empowers small businesses to run more efficiently and scale faster.

Since completing its seed funding round in 2023, Shipday has continued to successfully scale its platform globally with more than 5,000 businesses in over 100 countries worldwide, and the platform is available in 30 languages.

“This milestone marks a pivotal moment for Shipday as we continue to scale our platform to meet the growing needs of SMBs navigating complex delivery logistics,” said Moin Islam, Co-Founder and CEO at Shipday. “We’re thrilled to partner with ECP Growth and Ibex, who understand the operational challenges many SMBs face and share our vision for scalable, intuitive logistics technology. Their strategic guidance and deep sector expertise will help us accelerate innovation and reach more customers globally.”

“In an increasingly digital-driven marketplace, Shipday’s mission of empowering SMBs to reach more customers though scalable logistics solutions resonated deeply with ECP’s investment approach,” said Jeff Emmons, Director at ECP Growth. “Shipday’s AI-enabled platform is purpose-built to drive efficiency, mobility, and resource efficiency and to create sustainable value for businesses as they scale. We’re excited to co-lead this investment alongside Ibex, and we look forward to working closely with the Shipday team to expand the platform’s impact.”

“Shipday is equipping SMBs with the necessary tools to compete and win in the last-mile delivery space that has seen explosive growth and high consumer expectations. We’re proud to partner with the company and ECP Growth to co-lead the Series A,” said Jeff Peters, Partner at Ibex Investors and Head of Mobility VC. “We look forward to supporting Shipday as it accelerates its growth and redefines what’s possible for last-mile logistics.”

About Shipday
Shipday is a global delivery and logistics technology platform serving small and medium-sized businesses in over 100 countries. Shipday partners with restaurants, bakeries, grocers, flower shops, and other local merchants to streamline their local delivery logistics and enhance customer satisfaction through AI-powered delivery automation and customer engagements. In addition to serving SMBs, the platform has capabilities to power direct delivery for large, global franchise brands, providing flexibility for businesses of all sizes. For more information, please visit www.shipday.com.

About ECP Growth
ECP Growth is a growth stage investment firm that partners with entrepreneurial businesses creating products, solutions, and technologies across the consumer value chain. ECP Growth takes a thematic approach to investing in companies that sit within resilient categories and have attractive growth fundamentals, with a goal of long-term value creation. For more information, please visit www.ECPgrowth.com

About Ibex Investors
Ibex Investors is a US-based investment firm focused on distinct geographic and thematic strategies and manages a variety of private funds. Ibex is headquartered in Denver, CO, with investment professionals spread across New York, Tel-Aviv, and Silicon Valley.

The Ibex Mobility Revolution VC strategy focuses on high-conviction early-stage investments in mobility, logistics, and manufacturing startups.

More information on Ibex Investors can be found at www.ibexinvestors.com

Contacts:

Shipday
Moin Islam
[email protected]
415-770-3352

ECP Growth
Marissa Foray
[email protected]
203-321-5461

Kate Thompson / Heather Milke
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449

Ibex Investors
Lian Swirsky
[email protected]
+972-50-2846262

SOURCE Shipday